Mar 31, 2022

Sotera Health Q1 2022 Earnings Report

Sotera Health's first-quarter performance in 2022 reflected double-digit top-line and bottom-line growth, driven by volume, mix, and pricing, while reaffirming the 2022 outlook.

Key Takeaways

Sotera Health reported a 12% increase in net revenues to $237 million for Q1 2022, with net income rising to $31 million, or $0.11 per diluted share. The company reaffirmed its 2022 financial outlook, focusing on execution and capacity building to meet future demand.

Net revenues for Q1 2022 reached $237 million, a 12% increase compared to Q1 2021.

Net income for Q1 2022 was $31 million, or $0.11 per diluted share, compared to $11 million, or $0.04 per diluted share in Q1 2021.

Adjusted EBITDA for Q1 2022 increased by 10% to $115 million compared to the prior-year quarter.

The company reaffirmed its 2022 financial outlook, initially provided on March 1, 2022.

Total Revenue
$237M
Previous year: $212M
+11.6%
EPS
$0.22
Previous year: $0.18
+22.2%
Adjusted EBITDA
$115M
Previous year: $105M
+9.5%
Net Leverage Ratio
3.4
Previous year: 4.1
-17.1%
Gross Profit
$129M
Previous year: $115M
+11.7%
Cash and Equivalents
$121M
Previous year: $108M
+12.0%
Free Cash Flow
$14.4M
Previous year: $35.2M
-59.1%
Total Assets
$2.84B
Previous year: $2.78B
+2.1%

Sotera Health

Sotera Health

Sotera Health Revenue by Segment

Forward Guidance

Sotera Health reaffirmed its 2022 outlook, with net revenues expected to be in the range of $1.0 billion to $1.03 billion, representing growth of approximately 7% to 11%. Adjusted EBITDA is projected to be between $515 million and $535 million, reflecting growth of approximately 7% to 11%. Adjusted EPS is anticipated to be in the range of $0.93 to $0.99, up 6% to 13% versus the prior year.

Positive Outlook

  • Net revenues in the range of $1.0 billion to $1.03 billion, representing growth of approximately 7% to 11%, compared to the prior year.
  • Adjusted EBITDA in the range of $515 million to $535 million, representing growth of approximately 7% to 11%, compared to the prior year.
  • Tax rate applicable to Adjusted Net Income in the range of 29% to 30%.
  • Adjusted EPS in the range of $0.93 to $0.99, representing growth of 6% to 13% versus the prior year.
  • Net leverage reduction of approximately 1⁄2 of a turn.

Challenges Ahead

  • Supply chain continuity, particularly for the supply of ethylene oxide (“EO”) and cobalt-60 (“Co-60”).
  • The impact of inflationary trends including the impact on the supply of labor.
  • The impact of the COVID-19 pandemic including the rate of recoveries of elective procedures and new product development testing.
  • The expectation that exchange rates as of Q1 2022 remain constant for the remainder of 2022.
  • Known and unknown risks and uncertainties, including those set forth below under “Forward-Looking Statements.”

Revenue & Expenses

Visualization of income flow from segment revenue to net income